A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Summary
Third Opinion Trial Synopsis:
This study is comparing two treatments for adults with a type of cancer called Multiple Myeloma. The first treatment is a medicine called ide-cel and the second treatment is another medicine called lenalidomide (LEN). The study wants to see which treatment is more effective, safe, and easy for patients to tolerate. The participants in the study have been recently diagnosed with Multiple Myeloma and have not responded as well as expected to a certain procedure called autologous stem cell transplantation (ASCT). The researchers want to know if ide-cel combined with lenalidomide is better than just lenalidomide alone for these patients.
This study is comparing two treatments for adults with a type of cancer called Multiple Myeloma. The first treatment is a medicine called ide-cel and the second treatment is another medicine called lenalidomide (LEN). The study wants to see which treatment is more effective, safe, and easy for patients to tolerate. The participants in the study have been recently diagnosed with Multiple Myeloma and have not responded as well as expected to a certain procedure called autologous stem cell transplantation (ASCT). The researchers want to know if ide-cel combined with lenalidomide is better than just lenalidomide alone for these patients.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: